Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity

22Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Overexpression of Shc adaptor proteins is associated with mitogenesis, carcinogenesis and metastasis. Multiple copies in T-cell malignancy 1 (MCT-1) oncoprotein promotes cell proliferation, survival and tumorigenic effects. Our current data show that MCT-1 is a novel regulator of Shc-Ras-MEK-ERK signaling and MCT-1 is significantly co-activated with Shc gene in human carcinomas. The knockdown of MCT-1 enhances apoptotic cell death accompanied with the activation of caspases and cleavage of caspase substrates under environmental stress. The cancer cell proliferation, chemo-resistance and tumorigenic capacity are proved to be effectively suppressed by targeting MCT-1. Accordingly, an important linkage between MCT-1 oncogenicity and Shc pathway in tumor development has now been established. Promoting MCT-1 expression by gene hyperactivation may be recognized as a tumor marker and MCT-1 may serve as a molecular target of cancer therapy. © Shih et al.

Author supplied keywords

Cite

CITATION STYLE

APA

Shih, H. J., Chen, H. H., Chen, Y. A., Wu, M. H., Liou, G. G., Chang, W. W., … Hsu, H. L. (2012). Targeting MCT-1 oncogene inhibits Shc pathway and xenograft tumorigenicity. Oncotarget, 3(11), 1401–1415. https://doi.org/10.18632/oncotarget.688

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free